Pure New Zealand Manuka Honey Gel for Chronic Ulcer Care
Understanding the Challenge of Chronic Wound Stalling
Chronic ulcers—particularly diabetic foot ulcers and venous leg ulcers—present one of the most persistent challenges in advanced wound care. These wounds often stall in the healing process due to excess matrix metalloproteinases (MMPs), bacterial colonization, and the risk of infection in exuding tissue. Patients and clinicians searching for a pure New Zealand Manuka honey gel for chronic ulcers are typically looking for a solution that addresses infection control, autolytic debridement, and moisture balance without introducing harsh chemical antiseptics. Roosin Medical Co., Ltd., a global medical device manufacturer founded in 1996, has built its Advanced Wound Care product line specifically around these clinical pain points.
What Makes Manuka Honey Gel Effective for Chronic Ulcers
Roosin Medical’s Manuka Honey Gel is formulated using 100% pure New Zealand medical-grade Manuka honey. This positioning reflects a clear strategic focus: delivering continuous antibacterial protection, osmotic autolytic debridement, and an optimal moist healing environment for both human medicine and veterinary care, including applications for dogs, cats, and horses.
Key Features of the Formulation
- 100% New Zealand Manuka honey: Rich in natural Methylglyoxal (MGO), this component exerts continuous broad-spectrum antibacterial activity, eliminates foul wound odor, and discourages biofilm formation without relying on synthetic antibiotics.
- High osmotic gradient: By drawing interstitial fluid outward, the gel gently softens and detaches stubborn necrotic slough, facilitating painless, non-surgical autolytic debridement.
- Non-toxic, bio-friendly profile: The formulation is non-cytotoxic and non-stinging, meaning it will not harm tissue beds and remains safe even if accidentally licked in trace amounts by companion animals during grooming.
- High-viscosity protective gel: This texture clings securely to vertical or active surfaces, allowing it to stay firmly in place on irregular contours, mobile joints, and beneath secondary bandages.
Addressing the Core Pain Points of Chronic Wounds
The target scenario for this product centers on several well-documented pain points in wound management: bacterial colonization, infection risks, and wound malodor in chronic ulcers and traumatic tears. The differentiated value proposition is built on a combination of high MGO broad-spectrum antimicrobial action, high osmotic autolytic debridement, and a non-toxic, safe formulation. Together, these properties clear infection and necrotic slough while remaining non-stinging and safe for sensitive applications.
Technical Standards Behind the Product
Roosin Medical manufactures its Manuka Honey Gel as a gamma-irradiated, sterile, single-use gel formulation that is 100% free of additives, preservatives, and chemical residues. Production takes place under ISO 13485 standards, meeting both human medical and veterinary wound care compliance requirements. This level of manufacturing discipline is consistent with the company’s broader regulatory profile, which includes EU MDR clearance through TÜV Rheinland and US FDA 510(k) clearance for its collagen dressings, along with ISO 13485:2016 and MDSAP compliance verified by BSI.
The gel is supplied as a physical product in 15g, 25g, and 50g tubes, as well as bulk dispensing formats, and supports private label and OEM customization. Distribution channels include hospital networks, veterinary clinics, equine care centers, and veterinary medical distributors.
A Complementary Option: Manuka Honey Alginate Dressing
For chronic ulcers presenting heavy exudate, Roosin Medical also offers a Manuka Honey Alginate Dressing, available in sheet and rope formats. This product combines 100% medical-grade Manuka honey with biodegradable calcium alginate fibers, delivering high exudate absorption alongside continuous antimicrobial protection. The dual-action synergy of bioactive Manuka honey and calcium alginate allows the dressing to convert absorbed exudate into a cohesive honey-gel matrix. This clears heavy discharge, drives painless autolytic debridement, controls infection and odor, and permits one-piece, non-adherent removal—an important consideration for patients with chronic exudative ulcers such as diabetic foot ulcers and venous leg ulcers.
This alginate dressing is US FDA cleared and manufactured under ISO 13485 medical device quality management systems with ISO cleanroom standards, and is both latex-free and gamma-sterilized.
Documented Use in Chronic Ulcer Management
Roosin Medical’s wound care portfolio has been applied in chronic ulcer management scenarios. In one documented case, Collagen Powder was used to obliterate dead space in tunneling diabetic foot ulcers—addressing a common structural barrier to healing progression. Separately, in hospital transition scenarios involving deep or tunneling pressure injuries (Stage 3 and 4) and chronic ulcers, Collagen Dressings were implemented to bind destructive MMPs and obliterate cavity dead space. This resulted in an accelerated transition from the inflammatory phase to active granulation, successful obliteration of tunneling dead space, and a marked reduction in total wound closure duration. These cases illustrate how Roosin Medical’s broader Advanced Wound Care line is designed to work across different stages and types of chronic wound presentations.
Why Roosin Medical’s Approach Stands Out
Roosin Medical operates with a dual R&D footprint, maintaining centers in Shanghai and Taizhou that combine global biomedical talent with three decades of technical expertise in functional dressing lines and biomaterials. Manufacturing takes place in a 10,000 square meter facility equipped with ISO Class 7/8 cleanrooms and automated production, supporting consistent quality across the product range, including the Manuka Honey Gel.
The company’s stated value proposition—"Better Roosin, Better Life"—reflects an operational focus on pain reduction through atraumatic technology and clinical-grade efficacy. This is evident in the Manuka Honey Gel’s non-toxic, non-stinging profile, which avoids the tissue toxicity or stinging sensation sometimes associated with harsher chemical antiseptics.

With export coverage spanning 87 countries, and primary market focus in the United States (40%) and Europe (30%), Roosin Medical’s wound care solutions reach a wide range of clinical settings, from hospital chronic wound care centers to veterinary surgical hospitals and equine care facilities.
Conclusion
For those researching a pure New Zealand Manuka honey gel for chronic ulcers, Roosin Medical presents a formulation grounded in documented antimicrobial mechanisms, osmotic debridement action, and a non-toxic safety profile. Backed by regulatory clearances including EU MDR, US FDA 510(k), and ISO 13485 certification, and supported by three decades of biomaterials expertise, the company’s Advanced Wound Care line—anchored by the Manuka Honey Gel and complemented by the Manuka Honey Alginate Dressing—offers a structured response to the persistent clinical challenges of chronic, stalled wound healing.
https://www.roosin.com/
Roosin Medical Co., Ltd.